EGFR and glioblastoma: High-risk groups were closely correlated with older age at diagnosis, higher Karnofsky performance score (KPS), higher WHO grade, glioblastoma (GBM) phenotype, classical or mesenchymal subtype, Chr 7 gain/Chr 10 loss, non-codeleted 1p/19q, wild type IDH, unmethylated MGMT promoter, mutant TERT promoter, mutant PTEN, wild type ATRX, wild type TP53, and mutant EGFR.